<unk> , sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is taken by mouth. Common side effects include sleepiness, dizziness, tiredness, and numbness.<unk>  was approved in the United States in October 2019 and became available in February 2020. It was developed by Eli Lilly. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Lasmiditan
Dietitian
Serenic
Gutter oil
Riken
Pedestrian
Balm in Gilead 
Cochrane 